Brain+ announces first day of trading in new shares from the TO 4 warrant exercise and the related directed issue
Copenhagen, Denmark, 7 October 2024– Brain+ A/S (Nasdaq First North: BRAINP)
On 1 October 2024, Brain+ A/S (“Brain+” or “the Company”) announced that 38,522,165 of its warrants of series TO4 (the ‘Warrants’) had been exercised for subscription of 38,522,165 new shares and the decision to carry out a directed issue of 2,517,179 new shares to guarantors of the Warrant exercise (the “Directed Issue”). The TO 4 warrants were issued in connection with Brain+’ unit rights issue in June 2024. The new shares from both the Warrant exercise and the Directed Issue have now been registered with the Danish Business Authority and admitted for trading on Nasdaq First North Copenhagen from 8 October 2024.
After the completion and registration of the Warrant exercise and the Directed Issue with the Danish Business Authority, the number of shares in Brain+ have increased by 41,039,344 shares, from 171,501,141 shares to 212,540,485 shares, and the Company’s nominal share capital have increased by DKK 3,283,147.52, from DKK 13,720,091.28 to DKK 17,003,238.80.
After registration with the Danish Business Authority, all the new shares from both the Warrant exercise and the Directed Issue have now also been admitted for trading on Nasdaq First North Copenhagen under the ISIN-code for Brain+ shares: DK0061670205.
The first day of trading of the new shares will be 8 October 2024.
Advisors
In connection with the unit rights issue including the issue and exercise of warrants of series TO 4, Sedermera Corporate Finance AB act as financial advisors to Brain+. Markets & Corporate Law Nordic AB acts as legal advisor. Nordic Issuing AB is the issuing agent.
For more information about the warrant exercise, please contact:
Sedermera Corporate Finance AB
Phone: +46 (0) 40 615 14 10
E-mail: cf@sedermera.se
www.sedermera.se
For more information about Brain+, please contact:
Kim Baden-Kristensen, CEO Hanne Vissing Leth, CFO
Phone: +45 31 39 33 17 Phone: +45 53 88 99 02
E-mail: kim@brain-plus.com E-mail: hanne@brain-plus.com
Certified Adviser
Keswick Global AG
Phone: +43 1 740 408 045
E-mail: info@keswickglobal.com
Brain+ mission: Become the preferred provider of certified health tech solutions for better dementia management, servicing one million people affected by dementia in 2030.
